Smart Drug Delivery

$232,074U19FY2011AINIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 38928220 Paper 38339228 Paper 38182415 Paper 37460469 Paper 36980556 Paper 36441774 Paper 35446961 Paper 35149588 Paper 35101798 Paper 34621689 Paper 34615996 Paper 34613772 Paper 34208819 Paper 34087939 Paper 34033821 Paper 33854057 Paper 33684237 Paper 33679610 Paper 33603166 Paper 33126055 Paper 33110056 Paper 33035640 Paper 32438524 Paper 32289317 Paper 32289315 Paper 32275865 Paper 32219161 Paper 32215970 Paper 32134361 Paper 32080625 Paper 31883467 Paper 31419518 Paper 31295086 Paper 31201850 Paper 31071242 Paper 30981805 Paper 30928338 Paper 30879887 Paper 30861238 Paper 30855329 Paper 30804107 Paper 30762363 Paper 30680861 Paper 30674532 Paper 30626699 Paper 30552702 Paper 30531185 Paper 30525572 Paper 30499383 Paper 30385716 Paper 30333514 Paper 30320184 Paper 30226240 Paper 30217775 Paper 30198910 Paper 30184433 Paper 30177881 Paper 30150422 Paper 30055293 Paper 30050753 Paper 30029729 Paper 30009835 Paper 29964171 Paper 29939160 Paper 29935382 Paper 29895675 Paper 29802123 Paper 29755130 Paper 29747066 Paper 29610484 Paper 29584588 Paper 29581256 Paper 29437148 Paper 29391546 Paper 29245086 Paper 29242632 Paper 29140165 Paper 29053969 Paper 29035377 Paper 28985560 Paper 28835115 Paper 28661413 Paper 28619760 Paper 28438857 Paper 28347845 Paper 28306235 Paper 28212735 Paper 28202514 Paper 28145510 Paper 28064218 Paper 27984017 Paper 27982579 Paper 27941944 Paper 27842070 Paper 27842066 Paper 27794421 Paper 27773819 Paper 27701148 Paper 27636404 Paper 27591733

Abstract

Core E has several investigators with extensive expertise in drug delivery, synthetic/bioconjugation chemistry, and nanotechnology. The central function of Core E is to provide a "tool box" comprised of various types of delivery systems to accommodate different radiation protectors/mitigators that either have been or will be developed from different research projects in our CMCR. Specific services will be provided to 1) improve the bioavailability of testing compounds that are non-orally active and poorly water soluble by formulating them in nanoparticulates for testing of in vivo activity and toxicity;2) selectively deliver radiation mitigators to the cytoplasm or mitochondria of critical cell types in vital organs through the use of lipidic systems or lipid-coated biodegradable carbon nanotubes;and 3) to achieve controlled/slow release of the active ingredients through either the emulsion particles with an oil core that is made of fat with high melting temperature or through triggered release from the nanotubes

View original record on NIH RePORTER →